Key Takeaways Bayer and Kumquat begin a phase I study of KQB548 for KRAS G12D-mutated tumors.The study will assess the safety and early efficacy in pancreatic, colorectal and lung cancers.KQB548 is the lead program from Bayer and Kumquat's exclusive oncology collaborationBayer (BAYRY) , along with San Diego, CA-based, privately held company, Kumquat Biosciences, announced the initiation of a phase I study evaluating their investigational inhibitor, KQB548 (BAY 3771249), which is being developed for treating ...